

EUR Twin-Win Certificate

Linked to FTSE MIB
Issued by UBS AG, London Branch



Cash Settled

SVSP Product Type: Twin-Win Certificate (1340)

Valor: 41480045

Final Terms

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, Investors in this Product are not eligible for the specific investor protection under the CISA. Moreover, Investors in this Product bear the issuer risk.

This document (Final Terms) constitutes the Simplified Prospectus for the Product described herein; it can be obtained free of charge from UBS AG, P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). The relevant version of this document is stated in English; any translations are for convenience only. For further information please refer to paragraph «Product Documentation» under section 4 of this document.

1. Description of the Product

Information on Underlying

Underlying(s)	Initial Underlying Level	Strike Level (100.00%)	Kick-Out Level (50.25%)	Conversion Ratio
FTSE MIB Bloomberg: FTSEMIB / Valor: 1603325	23,734.22	23,734.22	11,926.4500	1:0.0421

Product Details

Security Numbers Valor: 41480045 / ISIN: CH0414800455 / WKN: UW4HFZ

Issue Size Up to 15,000 Units (with reopening clause)

Issue Price EUR 1,000 (unit quotation)

Denomination/Nominal EUR 1,000 Settlement Currency EUR

Quoting Type Secondary market prices are quoted dirty; accrued interest is included in the price.

Dates

Launch Date16 May 2018Pricing Date ("Pricing")16 May 2018Payment Date (Issue Date)23 May 2018

Last Trading Day/Time 23 May 2023 / 17:15 CET

Expiration Date ("Expiry") 23 May 2023 (subject to Market Disruption Event provisions)

Redemption Date 30 May 2023 (subject to Market Disruption Event provisions)

Contact: UBS AG, P.O. Box, 8098 Zürich

Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Banks and Intermediaries: +41-44-239 76 76*

Redemption

The Investor is entitled to receive from the Issuer an amount in the Settlement Currency, according to the following scenarios:

Scenario 1 If NO Kick-Out Event has occurred, Investors will receive an amount according to the

following formula:

Nominal * (1 + Abs|Underlying Performance|)

Scenario 2 If a Kick-Out Event has occurred, the Investors will receive on the Redemption Date an

amount equivalent to the expiration value of the Underlying, taking into account the

Conversion Ratio.

Official closing level of the Underlying on the Expiration Date, as determined by the **Expiration Value**

Index Sponsor(s).

 $\frac{ExpirationValue}{InitialUnderlyingLevel} - 1$ **Underlying Performance**

Kick-Out Event A Kick-Out Event shall be deemed to occur if, at any time on any Exchange Business Day

> during the period from and including the Pricing Date to and including the Expiration Date, the level of the Underlying quoted by the Related Exchange is at or below the

respective Kick-Out Level, as reasonably determined by the Calculation Agent.

Product Structure

With a Twin-Win Certificate Investors can participate in the absolute performance of the Underlying while at the same time benefiting from a conditional downside protection as long as the Kick-Out Level is not breached.

If the Underlying breaches the Kick-Out Level, the conditional protection as well as the enhanced downside participation will cease to apply and the holder will receive an amount equivalent to the expiration value of the underlying since the pricing date, taking into account the Conversion Ratio.

General Information

UBS AG, Zurich and Basel, Switzerland, acting through its London Branch Issuer

A1 Moody's / A+ S&P's / AA- Fitch Issuer Rating

Swiss Financial Market Supervisory Authority (FINMA). London Branch additionally Issuer Supervisory Authority

Financial Conduct Authority (FCA) and Prudential Regulation Authority (PRA). Jersey

Branch additionally Jersey Financial Services Commission (JFSC).

UBS AG, Zurich (UBS Investment Bank) Lead Manager

Calculation Agent UBS AG, London Branch Paying Agent **UBS Switzerland AG**

Related Exchange The exchanges on which components comprising the Underlying are traded, as

determined by the Index Sponsor from time to time.

Index Sponsors Borse Italiana

Listing None

The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, Secondary Market

> to provide bid prices for this Product upon request in percentage and dirty (i.e. accrued interest is included). However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide bid prices for this Product and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices. Daily price indications, if any, will be available on www.ubs.com/keyinvest and SIX

Financial Information and, as the case may be, on Reuters/Bloomberg.

Interest Calculation 30/360

Business Day Convention Following Unadjusted

Business Day TARGET2

Minimum Investment 1 Unit(s) (subject to selling restrictions)

Minimum Trading Lot 1 Unit(s)

Clearing SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS AG, in

UBS AG, P.O. Box, 8098 Zürich Contact: Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Banks and Intermediaries: +41-44-239 76 76*

Switzerland)

Form of Deed **Uncertificated Securities**

Governing Law / Jurisdiction Swiss / Zurich

The terms of the Product may be subject to adjustments during its lifetime. For clients Adjustments

outside of the United Kingdom, any changes with regard to the terms of this Product shall be published on the internet at www.ubs.com/keyinvest. Detailed information on

such adjustments is to be found in the Product Documentation.

Public Offering Switzerland

Distribution Fee 0.20% p.a., fee included in the Issue Price

Tax Treatment Switzerland

97.80% (EUR 977.99 per Nominal) Bond floor at issue

Swiss Transfer Stamp Duty For Swiss Stamp Duty purpose, the product is treated as analogous to a bond. Therefore,

secondary market transactions are in principle subject to Swiss Stamp Duty (TK22).

For tax purposes this product is qualified as a combination of an option and bond, where Swiss Income Tax

the majority of the return of the bond part is in the form of a discount or of one payment on redemption date (IUP). For private investors with tax domicile in Switzerland

the increase of the value of the bond part (according to the "Modifizierte

Differenzbesteuerung") at sale or maturity is subject to Swiss federal as well as cantonal and communal income tax. Such an investor is taxed on the difference between the bondfloor at purchase* and the bond floor at sale or redemption*. However, any gain derived from the option is considered as capital gain and is therefore for such investors

subject to neither Swiss federal nor cantonal and communal income tax.

* each to be converted into CHF at the prevailing exchange rate at purchase and sale or

redemption (if applicable).

Swiss Withholding Tax This product is not subject to the Swiss Issuer Withholding Tax. It depends on the

jurisdiction of the issuer whether a foreign issuer withholding tax applies.

The tax information only provides a general overview over the Swiss tax consequences linked to this product based on the tax laws and the practice of the tax administration at the time of issue. Tax laws and the practice of tax administrations may change, possibly with retroactive effect.

Classification

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, Investors in this Product are not eligible for the specific investor protection under the CISA. Moreover, Investors in this Product bear the issuer risk.

Furthermore, this Product does not benefit from any depositor protection under Art. 37a under the Swiss Federal Law on Banks and Savings Banks (Banking Act) or other forms of deposit insurance under any other law as might be applicable to this Product.

2. Prospects of Profits and Losses

Investors in this Product expect the Underlying to trade positively or slightly negatively. Market Expectation

In any case Investors expect that the Kick-Out Level will not be breached.

Effect of the performance of the Underlying on redemption amount or on delivery obligation:

- Positive Performance If the Underlying perform positively, Investors realise a positive return.

Sideways to slightly negative If the Underlying perform sideways to slightly negative, Investors still realise a positive performance

Pronounced negative performance If the Underlying performs negatively and additionally the Kick-Out Level has been

breached, Investors may lose some or all of their investment.

Maximum Return The profit potential is unlimited.

Maximum Loss Investors may lose some or all of the investment as they are fully exposed to the

performance of the Underlying.

UBS AG, P.O. Box, 8098 Zürich Contact: Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Banks and Intermediaries: +41-44-239 76 76*

3. Significant Risks for Investors

General risk warning Potential Investors should understand the risks associated with an investment in the

Product and shall only reach an investment decision after careful considerations with their legal, tax, financial and other advisors of (i) the suitability of an investment in the Product in the light of their own particular financial, fiscal and other circumstances; (ii) the information set out in this document and (iii) the Underlying(s). The following is a summary of the most significant risks. Further risks are set out in the Product

Documentation.

Risk Tolerance Investors in this Product should be experienced Investors and familiar with both

> derivative products and the stock markets. Although Investors benefit from a predefined, regular coupon payment, they must be willing to make an investment that

is exposed to the full down-side risk of the Underlying.

Product specific risks

Loss Potential Investors may lose some or all of the investment as they are fully exposed to the

performance of the Underlying.

Capital Protection (at Expiry) None

investment in the Underlying

Risk Potential in comparison to a direct The Kick-Out Level limits the risk exposure compared to a direct investment. However, once the Kick-Out Level is breached, the risk potential is similar as with a direct

investment in the Underlying.

Issuer Call right None Stop Loss Event None

Extraordinary termination risk The Product contains terms and conditions that allow the Issuer to terminate and

redeem the Product prior to the Redemption Date. In case of such extraordinary termination, the Issuer shall pay to the Investors an extraordinary termination amount as determined by the Calculation Agent which is usually equivalent to the market value of the Product. Potential Investors should note that the extraordinary termination amount may deviate from and may be considerably below the amount which would be payable pursuant to the final redemption provisions on the Redemption Date. Investors are not entitled to request any further payments on the Product following

the termination date

Adjustment risk Potential Investors should be aware that it cannot be excluded that certain events

occur or certain measures are taken (by parties other than the Issuer) in relation to the Underlying(s) which can lead to changes to the Underlying(s) or its concept (e.g. corporate events of a company whose shares constitute an Underlying, market disruption events or other circumstances affecting normal activities). In the case of the occurrence of such events or measures, the Issuer and/or the Calculation Agent are entitled to effect adjustments according to the Product Documentation. Such

adjustments might have a negative impact on the value of the Product.

Illiquidity risk in secondary market The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and/or offer prices for this Product on a regular basis.

However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and/or offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or

determination of such prices.

Potential Investors therefore should not rely on the ability to sell this Product at a specific time or at a specific price. Potential Investors should note that prices quoted typically include a spread and therefore may deviate from the market value of the Product. In special market situations, where the Issuer is completely unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices in the secondary market may be temporarily expanded, in order to limit the economic risks of the Issuer. Hence, Investors might sell at a price considerably lower than the actual price of the Product at the time of its sale. By selling the Product in the secondary market Investors may

receive less than the capital invested.

In case of a secondary market transaction, there is a possibility that costs, including taxes, related to or in connection with the Product may arise for Investors that are not

paid by the Issuer or imposed by the Issuer.

UBS AG, P.O. Box, 8098 Zürich Contact:

Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Banks and Intermediaries: +41-44-239 76 76*

5/7 Valor: 41480045 Final Terms

Market Disruption risk

Investors are exposed to market disruption events (such as trading disruption, exchange disruption and early closure of the relevant exchange), which could have an impact on the redemption amount through delay in payment, change in value or suspension of trading in the Product in the secondary market. For a detailed description of such events and their effects please refer to the Product Documentation.

Withholding tax

Investors in this Product should note that any payment under this Product may be subject to withholding tax (such as, inter alia, Swiss Withholding Tax, and/or withholding related to FATCA or 871(m) of the US Tax Code). **Any payments due under this Product are net of such tax.** Please refer to the General Terms and Conditions for detailed information. If the Issuer is required to withhold any amount pursuant to Section 871(m) or FATCA of the U.S. Tax Code, the Issuer will not be required to pay additional amounts with respect to the amount so withheld.

Risk Factors relating to the Issuer

In addition to the market risk with regard to the development of the Underlying, each Investor bears the general risk that the financial situation of the Issuer could deteriorate. The Products constitute immediate, unsecured and unsubordinated obligations of the Issuer, which, particularly in case of insolvency of the Issuer, rank pari passu with each and all other current and future unsecured and unsubordinated obligations of the Issuer, with the exception of those that have priority due to mandatory statutory provisions. The general assessment of the Issuer's creditworthiness may affect the value of the Products. This assessment generally depends on the ratings assigned to the Issuer or its affiliated companies by rating agencies such as Moody's, Fitch and Standard & Poor's.

The Issuer Ratings indicated in this document reflect the situation at the time of issuance and may be subject to changes. The actual Issuer Ratings at any given time can be seen on the Issuer's website (www.ubs.com) under "Analysts & Investors".

4. Additional Information

Product Documentation

This document ("**Final Terms**") contains the Final terms for the Product. The prospectus requirements of Article 652a/Article 1156 of the Swiss Code of Obligations are not applicable.

These Final Terms together with the 'General Terms and Conditions for Structured Products on Equity, Commodity and Index Underlyings', stipulated in English and as amended from time to time ("General Terms and Conditions") shall form the entire documentation for this Product ("Product Documentation"), and accordingly the Final Terms should always be read together with the General Terms and Conditions. The Final Terms may be provided in various languages, however, only the English version will be relevant and any translations are for convenience only. Definitions used in the Final Terms, but not defined therein shall have the meaning given to them in the General Terms and Conditions.

The Product Documentation can be obtained free of charge from UBS AG, P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, for clients outside of the United Kingdom, the Product Documentation is available on the internet at www.ubs.com/keyinvest. Notices in connection with this Product shall be validly given by publication as described in the General Terms and Conditions. Furthermore, for clients outside of the United Kingdom, any changes with regard to the terms of this Product shall be published on the internet at www.ubs.com/keyinvest.

Important Information

The information herein is communicated by UBS AG and/or its affiliates ("**UBS**"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the Product to which this document relates. UBS may provide investment banking and/or other services to and/or have officers who serve as directors of the companies referred to in this document. UBS' trading and/or hedging activities related to this Product may have an impact on the price of the underlying asset(s) and may affect the likelihood that any relevant barrier(s) is/are crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price ("**Distribution Fees**"). Distribution Fees, if any, are disclosed in section 1 of this document and reflect the maximum amount a dealer or financial institution may receive from UBS; the actual amount may be lower.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

Contact: UBS AG, P.O. Box, 8098 Zürich

www.ubs.com/kevinvest

 $\textbf{Private Investors:} \ \textbf{Please contact your client advisor or send an email to keyinvest@ubs.com}$

Banks and Intermediaries: +41-44-239 76 76*

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment in the Product to which this document relates will be exclusively subject to the detailed provisions, including risk considerations, contained in the Product Documentation.

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS' prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for Investors that are not paid by UBS or imposed by it. Please refer to the Product Documentation for further information.

Index Disclaimer

FTSE MIB

The securities are not in any way sponsored, endorsed, sold or promoted by FTSE International Limited ("FTSE"), the London Stock Exchange Plc (the "Exchange") or The Financial Times Limited ("FT") (together the "Licensor Parties") and none of the Licensor Parties make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to (i) the results to be obtained from the use of the FTSE MIB INDEX (the "Index") (upon which the securities are based), (ii) the figure at which the Index is said to stand at any particular time on any particular day or otherwise, or (iii) the fitness or suitability of the Index for the particular purpose to which it is being put in connection with the securities. None of the Licensor Parties have provided or will provide any financial or investment advice or recommendation in relation to the Index to UBS AG or to its customers or clients. The Index is calculated by FTSE or its agent. None of the Licensor Parties shall be liable (whether in negligence or otherwise) to any person for any error in the Index and none of the Licensor Parties shall be under any obligation to advise any person of any error therein.

All rights in the Index vest in FTSE. "FTSE®" is a trade mark of the Exchange and the FT and is used by FTSE under licence.

Selling Restrictions

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.

Europe - Any public offer of this Product within an EEA jurisdiction (EU member states plus Norway, Iceland and Liechtenstein) shall only be possible if compliant with the requirements of the EUPD and with the law of that jurisdiction.

If the prospectus either does not qualify as a prospectus published in accordance with the requirements of the EUPD or is not filed with or notified to the relevant Financial Supervisory Authority, this Product may not be offered or sold in EEA jurisdictions other than 1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies), provided that the offer is only being made in one or more EEA jurisdiction that will not, before the end of the offer period for the Securities, have implemented the provision under the Directive 2010/73/EU (the "PD Amending Directive") that increases this minimum denomination (or total consideration per investor) to EUR 100,000; or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 or, if the relevant EEA jurisdiction has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons that are not Qualified Investors per EEA jurisdiction. "Qualified Investors" are persons or entities as defined in the Prospectus Directive.

For information on public offering in EEA jurisdictions please see under section "General Information" above.

Hong Kong - Each purchaser has represented and agreed that it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Products, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Products which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice

Singapore - This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this Product may not be circulated or distributed, nor may this Product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act (Chapter 289) of Singapore (the "SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1), and in accordance with the conditions of, any other applicable provision of the SFA.

Where this Product is subscribed or purchased under Section 275 of the SFA by a relevant person which is:

- (a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
- (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor.

securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant of an offer made under Section 275 of the SFA except:

- (1) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276 (4)(i)(B) of the SFA;
- (2) where no consideration is or will be given for the transfer;
- (3) where the transfer is by operation of law; or
- (4) as specified in Section 276 (7) of the SFA; or
- (5) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

Contact: UBS AG, P.O. Box, 8098 Zürich Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Internet: www.ubs.com/keyinvest Banks and Internediaries: +41-44-239 76 76*

7/7 Valor: 41480045 Final Terms

UK - For the purpose of non-discretionary accounts, this Product should not be sold with a consideration of less than EUR 100,000 or equivalent.

USA - This Product may not be sold or offered within the United States or to U.S. persons.